pharmaceuticals - Page 2

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

While the public wants more pharmaceuticals and biotech advancements to treat the endless number of ailments or to extend their lives, there is a simultaneous push to make drugs more ...
Read Full Story »

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) made a handy gain to start out the week after the firm, in conjunction with Pfizer Inc. (NYSE: PFE), announced updated results from a mid-stage ...
Read Full Story »

Tuesday’s Biggest Biotech Movers

Despite this truncated trading week, Tuesday was a breakout day for a few biotech companies. In this case, all these companies saw a solid gain. With the markets back near ...
Read Full Story »

How Pfizer Is Looking to Expand Its Eczema Treatment

Pfizer Inc. (NYSE: PFE) has announced topline results from its most recent late-stage study in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis ...
Read Full Story »

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

Pfizer Inc. (NYSE: PFE) has released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy (DMD). While these results did not necessarily live up to ...
Read Full Story »

Short Sellers Seek Direction on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Are Allergan Shareholders Getting Enough in the AbbVie Acquisition?

Allergan PLC (NYSE: AGN) shares jumped on Tuesday after the company announced that it would be acquired by AbbVie Inc. (NYSE: ABBV) in a cash and stock transaction. The transaction ...
Read Full Story »

High Hopes and Expectations for Merck’s First Investor Day in Years

Merck & Co. Inc. (NYSE: MRK) may still be up in 2019, and it may be better off for now than rival Pfizer, but the reality is that Merck shares ...
Read Full Story »

Multimillion-Dollar Medical Claims Continue to Skyrocket

Whether you were in favor of or against the Affordable Care Act, aka Obamacare, it is likely of little surprise that the cost of health care has continued to rise. ...
Read Full Story »

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

New Sickle Cell Disease Treatment Could Be a Blockbuster With $1 Billion in Sales

Sickle cell disease impacts about 100,000 Americans, according to RethinkSCD.com. The incidence is about one in every 365 African American births and about one in every 16,300 Hispanic American births. ...
Read Full Story »

5 ASCO Winners That Could Still More Than Double

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) has just concluded, and there were some significant moves we saw as a result. Wedbush took a closer ...
Read Full Story »

AstraZeneca Cuts Almost All Ties to Inovio Pharma

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca PLC (NASDAQ: AZN) would be scaled back. AstraZeneca subsidiary MedImmune is ...
Read Full Story »

Big Pharma Short Sellers Hike Their Bets

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »